Aktuelle Studien zum Harnblasenkarzinom

Sie befinden sich hier:

Studientitel Status Seit Medikation
Incyte - A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations Aktiv 17.01.2018 Tyrosine Kinase Inhibitor INCB054828
WO29636 - A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION Aktiv Rekrutierung abgeschlossen Atezolizumab vs. Observation
GO29294 A phase III, open-label, multicenter, randomized study to investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) compared with chemotherapy in patients with locally advanced or metastatic Urothelial Bladder Cancer after Failure with Platinum-Containing Chemotherapy Aktiv Rekrutierung abgeschlossen MPDL3280A
GO35590 A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY In Planung   Atezolizumab +/- MOXR0916
POTOMAC: Phase III Randomized, Open-label, Multi-center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as Combination Therapy versus BCG alone in High Risk, BCG-Naïve Non-muscle-Invasive Bladder Cancer Patients In Planung   Durvalumab and BCG vs BCG alone
Ansprechpartner      
Dr. U. Steiner, A. Biniszkiewicz, Tel.: Tel.: 030-450 515288, Fax: 030-450 515927